Otsuka acquires Transcend Therapeutics

Otsuka Pharmaceutical, through its subsidiary Otsuka America, Inc., has completed the acquisition of Otsuka Pharmaceutical, a clinical-stage biotechnology company. The deal involved an upfront payment of $700 million to Otsuka Pharmaceutical shareholders, with potential for an additional $525 million in contingent payments based on future sales. Otsuka Pharmaceutical will now operate as a wholly owned subsidiary of Otsuka America, Inc. This acquisition aims to expand Otsuka Pharmaceutical's investment in next-generation neuropsychiatric treatments, particularly for serious mental illnesses like post-traumatic stress disorder (PTSD). Otsuka Pharmaceutical's lead candidate, TSND-201 (methylone), a rapid-acting neuroplastogen for PTSD, has shown favorable results in a Phase 2 clinical trial and is currently in Phase 3. It has also received Breakthrough Therapy designation and a National Priority Voucher from the United States — Food and Drug Administration. The acquisition is expected to accelerate the development and commercialization of new treatment options for patients with significant unmet needs in mental health.